MedTrace Logo

Ultra Phonophoresis With a Hyaluronic Acid-Containing Gel on Carpal Tunnel Syndrome Post Mastectomy.

NCT06538818 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-09-18

No results posted yet for this study

Summary

In this study, 60 patients will be randomly assigned into two equal groups (30 patients for each group):

1. Group A: This group will include 30 patients who will receive Ultra Phonophoresis with a hyaluronic acid-containing gel 5 sessions per week for 3 weeks in addition to their physical therapy program and medical treatment.
2. Group B: This group will include 30 patients who will receive only their traditional physical therapy program and medical treatment.

Criteria for the patient selection:

(A) Inclusion Criteria:

The subject selection will be according to the following criteria:

* Age range between 40-55 years.
* Female patients will participate in the study.
* All patients will have hormonal therapy at least for 6 weeks.
* All patients enrolled to the study will have their informed consent.
* Patient referred from physician by carpal tunnel syndrome. (B) Exclusion Criteria:

The potential participants will be excluded if they meet one of the following criteria:

* Marked lymphedema.
* Steroid injection for CTS.
* Thrombosis propensity.
* Cervical radiculopathy.
* Brachial plexopathy

Conditions

  • Mastectomy
  • Carpal Tunnel Syndrome (CTS)

Interventions

DEVICE

Ultra Phonophoresis

Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of a hyaluronic acid-containing gel will be applied gel pad over the wrist and along the course of median nerve at the carpal tunnel. The following parameters will be used: intensity of 1.0 W/em2 at a 1MHz frequency for 5 minutes and pulsed (25%) ultrasound waves to transfer the hyaluronic acid-containing gel. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks. The following parameters will be used: * intensity of 1.0 W/cm2 * 1MHz frequency * pulsed (25%) * 5 min/session, 5 d/wk, for 3 weeks.

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2024-10-01
Completion
2024-11-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06538818 on ClinicalTrials.gov